Literature DB >> 29117898

The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma.

Marie-Françoise Heymann1, Frédéric Lézot2, Dominique Heymann3.   

Abstract

Osteosarcoma is a rare primary bone cancer characterized by cancer cells producing calcified osteoid extracellular matrix and inducing lung metastases with a high frequency. The local microenvironment defined several tumor niches controlling the tumor growth and cell extravasation. The immune infiltrate composes one of these niches. The immune environment of osteosarcoma is mainly composed by T-lymphocytes and macrophages but also contains other subpopulations including B-lymphocytes and mast cells. Osteosarcoma cells control the recruitment and differentiation of immune infiltrating cells and establish a local immune tolerant environment favorable to the tumor growth, drug resistance and the occurrence of metastases. Osteosarcoma cells are able to affect the balance between M1 and M2 macrophage subtypes and so could control the T-lymphocyte responses via the PD-1/PDL-1 system. In addition, mesenchymal stem cells may also contribute to this immune tolerance and strengthen the immune evasion. The present review gives a brief overview of the immune components of osteosarcoma and their most recent therapeutic interests.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Immune tolerance; Immunotherapy; Osteosarcoma; Tumour microenvironment

Year:  2017        PMID: 29117898     DOI: 10.1016/j.cellimm.2017.10.011

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  63 in total

Review 1.  Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group.

Authors:  Ryan D Roberts; Michael M Lizardo; Damon R Reed; Pooja Hingorani; Jason Glover; Wendy Allen-Rhoades; Timothy Fan; Chand Khanna; E Alejandro Sweet-Cordero; Thomas Cash; Michael W Bishop; Meenakshi Hegde; Aparna R Sertil; Christian Koelsche; Lisa Mirabello; David Malkin; Poul H Sorensen; Paul S Meltzer; Katherine A Janeway; Richard Gorlick; Brian D Crompton
Journal:  Cancer       Date:  2019-07-29       Impact factor: 6.860

2.  Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory.

Authors:  Naiara Martinez-Velez; Virginia Laspidea; Marta Zalacain; Ana Patiño-García; Marta M Alonso; Sara Labiano; Marc García-Moure; Montse Puigdelloses; Lucía Marrodan; Marisol Gonzalez-Huarriz; Guillermo Herrador; Daniel de la Nava; Iker Ausejo-Mauleon; Juan Fueyo; Candelaria Gomez-Manzano
Journal:  Mol Cancer Ther       Date:  2022-03-01       Impact factor: 6.261

3.  Tumor-associated macrophages in osteosarcoma.

Authors:  Yi Zhao; Benzheng Zhang; Qianqian Zhang; Xiaowei Ma; Helin Feng
Journal:  J Zhejiang Univ Sci B       Date:  2021-11-15       Impact factor: 3.066

Review 4.  Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications.

Authors:  Tianyi Zhu; Jing Han; Liu Yang; Zhengdong Cai; Wei Sun; Yingqi Hua; Jing Xu
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

Review 5.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

Review 6.  Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s.

Authors:  Christopher DeRenzo; Stephen Gottschalk
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 7.  In vitro three-dimensional cell cultures for bone sarcomas.

Authors:  Javier Munoz-Garcia; Camille Jubelin; Aurélie Loussouarn; Matisse Goumard; Laurent Griscom; Axelle Renodon-Cornière; Marie-Françoise Heymann; Dominique Heymann
Journal:  J Bone Oncol       Date:  2021-07-06       Impact factor: 4.072

8.  Development of a Machine Learning-Based Autophagy-Related lncRNA Signature to Improve Prognosis Prediction in Osteosarcoma Patients.

Authors:  Guang-Zhi Zhang; Zuo-Long Wu; Chun-Ying Li; En-Hui Ren; Wen-Hua Yuan; Ya-Jun Deng; Qi-Qi Xie
Journal:  Front Mol Biosci       Date:  2021-05-21

9.  Long non-coding RNA X-inactive specific transcript promotes osteosarcoma metastasis via modulating microRNA-758/Rab16.

Authors:  Wei Liu; Qiuping Long; Li Zhang; Dehui Zeng; Bingbing Hu; Wei Zhang; Shengyao Liu; Songyun Deng; Li Chen
Journal:  Ann Transl Med       Date:  2021-05

10.  Development of a Novel Immune Infiltration-Related ceRNA Network and Prognostic Model for Sarcoma.

Authors:  Deyao Shi; Shidai Mu; Feifei Pu; Binlong Zhong; Binwu Hu; Jianxiang Liu; Tongchuan He; Zhicai Zhang; Zengwu Shao
Journal:  Front Cell Dev Biol       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.